![](/images/graphics-bg.png)
Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients
Joint Authors
Okamoto, Masanori
Yamanaka, Shintaro
Yoshimoto, Wataru
Shigematsu, Takashi
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-02
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Kidney transplant recipients develop secondary osteoporosis induced by immunosuppressive medication, with a high risk of fracture, and abdominal aortic calcification (AC) is a known predictor of cardiovascular mortality.
In this study of 12 stable kidney recipients, we estimated the preventive effect of bisphosphonate treatment on bone loss and progression of AC.
We randomly divided the subjects into a treatment group with alendronate (group A: 5 subjects) and a control group (group C: 7 subjects).
Group A patients received 35 mg/week of alendronate over 24 months, while group C patients were not administered with any bisphosphonates.
Two major endpoints were established: (1) the time-dependent change in bone mineral density (BMD) estimated with DEXA and (2) progression of abdominal AC, calculated twice as an index (ACI) using computed tomography data.
Over the 2-year study period, group A patients showed significantly increased BMD of 1.86 ± 0.85% ( P = 0.015 versus baseline), and almost complete inhibition of ACI progression (38.2 ± 24.2% to 39.6 ± 24.3%), but group C patients showed a decrease in BMD decline with bone loss and progression of ACI (32.8 ± 25.0% to 37.8 ± 29.2%, P = 0.061 ).
In conclusion, alendronate therapy was an effective treatment in kidney transplant recipients for secondary osteoporosis and vascular calcification as ectopic calcification.
This clinical trial is registered with number JMA-IIA00155 of JMACCT CTR.
American Psychological Association (APA)
Okamoto, Masanori& Yamanaka, Shintaro& Yoshimoto, Wataru& Shigematsu, Takashi. 2014. Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients. Journal of Transplantation،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1043284
Modern Language Association (MLA)
Okamoto, Masanori…[et al.]. Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients. Journal of Transplantation No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1043284
American Medical Association (AMA)
Okamoto, Masanori& Yamanaka, Shintaro& Yoshimoto, Wataru& Shigematsu, Takashi. Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients. Journal of Transplantation. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1043284
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1043284